1. Secretory prostate apoptosis response (Par)-4 sensitizes multicellular spheroids (MCS) of glioblastoma multiforme cells to tamoxifen-induced cell death
   Jayashree C. Jagtap et al, 2015 CrossRef
2. null
   Sepideh Mansouri et al, 2017 CrossRef
3. Design, synthesis and evaluation of alkylphosphocholine-gefitinib conjugates as multitarget anticancer agents
   Md. Maqusood Alam et al, 2017, Arch. Pharm. Res. CrossRef
4. Antiproliferative Effect of ASC-J9 Delivered by PLGA Nanoparticles against Estrogen-Dependent Breast Cancer Cells
   Paolo Verderio et al, 2014, Mol. Pharmaceutics CrossRef
5. Protein Kinase Targets in Breast Cancer
   Marilina García-Aranda et al, 2017, IJMS CrossRef
6. Dimethylsphingosine and miltefosine induce apoptosis in lung adenocarcinoma A549 cells in a synergistic manner
   Veselina Uzunova et al, 2019, Chemico-Biological Interactions CrossRef
7. Anticancer mechanisms and clinical application of alkylphospholipids
   Wim J. van Blitterswijk et al, 2013, Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids CrossRef
8. Prognostic Role of Human Epidermal Growth Factor Receptor 2 Status in Premenopausal Early Breast Cancer Treated With Adjuvant Tamoxifen
   Icro Meattini et al, 2013, Clinical Breast Cancer CrossRef
9. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
   Emily M Fox et al, 2013, Breast Cancer Res. CrossRef
10. Expression and Regulation of Prostate Apoptosis Response-4 (Par-4) in Human Glioma Stem Cells in Drug-Induced Apoptosis
    Jayashree C. Jagtap et al, 2014, PLoS ONE CrossRef
11. C-FLIP(L) contributes to TRAIL resistance in HER2-positive breast cancer
    Fenglin Zang et al, 2014, Biochemical and Biophysical Research Communications CrossRef
12. A dihydroselenoquinazoline inhibits S6 ribosomal protein signalling, induces apoptosis and inhibits autophagy in MCF-7 cells
    Esther Moreno et al, 2014, European Journal of Pharmaceutical Sciences CrossRef
13. LYN-activating mutations mediate antiestrogen resistance in estrogen receptor–positive breast cancer
    Luis J. Schwarz et al, 2014, J. Clin. Invest. CrossRef
14. Long Non-Coding RNA (lncRNA) Urothelial Carcinoma-Associated 1 (UCA1) Enhances Tamoxifen Resistance in Breast Cancer Cells via Inhibiting mTOR Signaling Pathway.
    Chihua Wu et al, 0 CrossRef
15. MED1 may explain the interaction between receptor tyrosine kinases and ERα66 in the complicated network of Tamoxifen resistance
    Sepideh Mansouri et al, 2017, European Journal of Pharmacology CrossRef
16. Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer - A comprehensive review from chemotherapy to immunotherapy.
    Parham Jabbarzadeh Kaboli et al, 2020, Pharmacol Res CrossRef
17. MicroRNA expression profiles of drug-resistance breast cancer cells and their exosomes
    Shanliang Zhong et al, 2016, Oncotarget CrossRef
18. Inhibitory effects of genistein in combination with gefitinib on the hepatocellular carcinoma Hep3B cell line
    Yongxi Tong et al, 2019, Exp Ther Med CrossRef
19. null
    Perla Pucci et al, 2020 CrossRef
20. Progress in the Understanding of the Mechanism of Tamoxifen Resistance in Breast Cancer.
    Jingwei Yao et al, 2020, Front Pharmacol CrossRef
21. Future perspectives for mTOR inhibitors in renal cell cancer treatment
    Anna M Czarnecka et al, 2015, Future Oncology CrossRef
22. Systemic Efficacy of Sirolimus via the ERBB Signaling Pathway in Breast Cancer
    Shinuk Kim, 2022, Processes CrossRef
23. Tamoxifen: The Past, Present, and Future of a Previous Orphan Drug
    Ghadier Matariek et al, 2022, EJMED CrossRef